MBM Commercial, led by Alexander Lamley, Director, recently assisted In4Derm, an innovative drug discovery company and winner of the 2109 Converge Challenge, in their seed investment round. The firm secured seed investment for their next-gen topical and oral therapies for widespread inflammatory conditions such as eczema and rheumatoid arthritis.
In4Derm spun out of Dundee University in July 2020 and specialize in the discovery of drugs, which are safe and effective, for the treatment of skin diseases. The funding was led by o2h Ventures.
“Alex[ander] and team have been with us from the outset,” noted Dr Andrew Woodland, Chief Scientific Officer. “From the Converge Challenge win through to this seed round, the support and advise from MBM has been invaluable.”
“MBM has been privileged to work alongside In4Derm on this investment.” said Alexander Lamley, MBM. “This investment provides the opportunity for continued develop of In4Derm’s pioneering skin therapies.”